Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GeneVax HIV vaccine
- Development stage
- Unknown
- Lead developer
- International AIDS Vaccine Initiative
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The GeneVax HIV vaccine is a prophylactic prime-boost vaccine candidate developed by Auro Vaccines for the prevention of HIV infection. The regimen utilizes a multiantigen DNA vaccine prime (HIV-MAG) encoding six HIV-1 proteins (Env, Gag, Pol, Nef, Tat, and Vif) co-administered with a DNA plasmid encoding human interleukin-12 (IL-12) as a genetic adjuvant. This prime is delivered via intramuscular electroporation using Ichor Medical Systems' TriGrid delivery system. The prime is followed by a boost with a recombinant adenovirus type 35 vector (Ad35-GRIN/ENV). Developed in partnership with the International AIDS Vaccine Initiative (IAVI), the vaccine is designed to elicit broad cell-mediated immunity, specifically CD4+ and CD8+ T cell responses. It has been evaluated in a Phase 1 clinical trial (B004) which demonstrated safety and tolerability.
- Brand names
- GeneVax
- Other names
- GeneVax HIV vaccineIAVI B004 vaccineHIV-MAG pDNA + GeneVax IL-12 / Ad35-GRIN/ENV
02
Targets
Tat (HIV-1 Tat)HIV-1 Pol polyproteinGag (HIV-1 Gag polyprotein)IL-12R (Interleukin-12 receptor)CD46 (CD46 Molecule)Vif (HIV-1 Vif)Nef (HIV-1 Nef)
Beyond the preview
Go deeper on GeneVax HIV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeneVax HIV vaccine.